Bioventus BVS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Net Sales by Business | ||||||
| International Segment | $15.64M-15.0% | $18.41M+20.0% | $15.34M-18.8% | $18.89M+41.4% | $13.36M-27.5% | |
| U.S. Segment | $116.45M-16.5% | $139.49M+13.1% | $123.31M-4.2% | $128.78M+16.5% | $110.52M-18.3% | |
| Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items by Business | ||||||
| International Segment | $2.77M-41.2% | $4.71M+48.9% | $3.17M-40.0% | $5.28M+145% | $2.16M-43.8% | |
| U.S. Segment | $21.14M-33.9% | $32M+36.5% | $23.44M-17.7% | $28.48M+67.0% | $17.06M-30.1% | |
| Adjusted other segment expense by Business | ||||||
| International Segment | -$120K— | $0-100% | $16K-90.6% | $170K+8,400% | $2K+101% | |
| U.S. Segment | -$252K-411% | $81K-59.5% | $200K-45.4% | $366K-59.3% | $899K+2,293% | |
| Adjusted cost of sales by Business | ||||||
| International Segment | $6.34M-10.2% | $7.06M+19.8% | $5.89M-12.7% | $6.75M+30.8% | $5.16M-21.2% | |
| U.S. Segment | $24.9M-21.4% | $31.67M+11.0% | $28.54M+1.1% | $28.22M+11.1% | $25.4M-24.9% | |
| Adjusted research and development expense by Business | ||||||
| International Segment | $0-100% | $16K+300% | $4K-77.8% | $18K+500% | $3K-70.0% | |
| U.S. Segment | $2.29M-19.0% | $2.83M+4.7% | $2.7M-7.5% | $2.92M+3.3% | $2.83M-9.9% | |
| Adjusted general and administrative expense by Business | ||||||
| International Segment | $2.58M+5.1% | $2.46M+2.8% | $2.39M-5.2% | $2.52M+28.1% | $1.97M-58.2% | |
| U.S. Segment | $24.24M-3.0% | $24.99M+2.4% | $24.4M-1.6% | $24.79M+6.3% | $23.32M-4.1% | |
| Adjusted selling expense by Business | ||||||
| International Segment | $3.32M-0.1% | $3.33M+13.0% | $2.94M-8.6% | $3.22M+0.7% | $3.2M+11.8% | |
| U.S. Segment | $38.24M-9.1% | $42.09M+11.0% | $37.92M+1.5% | $37.35M+7.6% | $34.72M-20.0% | |
| Adjusted marketing expense by Business | ||||||
| International Segment | $753K-11.8% | $854K-8.2% | $930K-0.3% | $933K+7.1% | $871K+11.2% | |
| U.S. Segment | $5.89M+0.9% | $5.83M-4.7% | $6.12M-8.1% | $6.66M+5.5% | $6.31M+2.0% | |
| Total Net Sales by Product | ||||||
| Pain Treatments | $63.43M-20.4% | $79.66M+18.6% | $67.18M-8.4% | $73.31M+24.4% | $58.92M-14.9% | |
| Restorative Therapies | $20.64M-9.1% | $22.71M+6.6% | $21.31M-1.5% | $21.64M+9.7% | $19.72M-35.8% | |
| Surgical Solutions | $48.03M-13.5% | $55.53M+10.7% | $50.17M-4.8% | $52.72M+16.5% | $45.23M-15.8% | |
| Total Net Sales by Geography | ||||||
| International | $15.64M-15.0% | $18.41M+20.0% | $15.34M-18.8% | $18.89M+41.4% | $13.36M-27.5% | |
| U.S. | $116.45M-16.5% | $139.49M+13.1% | $123.31M-4.2% | $128.78M+16.5% | $110.52M-18.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bioventus break its business down?
- Bioventus (BVS) reports total net sales by business across 2 parts — International Segment and U.S. Segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Bioventus's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bioventus's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
